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g/10.1016/j.jccw.2016.0Abstract In order to assess the impact of comorbidities and identify factors that accelerate the heal-
ing rate of venous leg ulcers we performed an extensive, retrospective analysis of our experience in a
diverse population. From June, 2006 to June, 2014, 897 patients with 1249 venous leg ulcers were
treated at Lake Wound Clinics. Treatment protocols utilized the standard regimen of wound clean-
ing, debridement and compression bandaging. Wound cleaning, autolytic debridement, packing and
dressing of venous leg ulcers utilized aqueous solutions of hypochlorous acid (HCA) rather than the
standard normal saline. This protocol caused all ulcers to close completely. Comorbidities that de-
layed healing included uncontrolled or poorly controlled diabetes mellitus, advanced peripheral ar-
tery occlusive disease (PAD), active smoking, use of steroid medications and/or street drugs, large
initial ulcer size and significant depth. Other factors, including advanced age, recurrent venous ul-
ceration, stasis dermatitis, lipodermatosclerosis, morbid obesity and infection with one or more
multidrug resistant organisms did not delay closure. From this experience we conclude that venous
leg ulcer care protocols that clean, debride, pack and dress with hypochlorous acid solutions can
reduce the effects of some comorbidities while accelerating healing times. Additional benefits are
described.
 2016 The Author. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
‘‘Chronic venous insufficiency’’ manifests as a cornu-
copia of clinical problems. The mildest of these istory, Lake District Hospital, 700
0, USA. Tel.: 11 541 517 5169
1 947 3339.
The Author. Published by Elsevier Inc.
d/4.0/).
1.001dependent edema that is readily relieved by elevation.
The most severe is venous ulceration. Venous insufficiency
is progressive and worsens over time. In the United States,
it is estimated that 1% of the adult population,
i.e., approximately 3.2 million people, have late stage
venous insufficiency and either have, or are at risk for
development of, venous leg ulcers.1 Although there are
multiple factors that produce venous valvular incompetence
in the superficial, deep and perforating veins, the end result
is the same. Venous congestion and pooling cause increasedThis is an open access article under the CC BY-NC-ND license (http://
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protein and formed blood elements leak into the interstitial
space and cause fibrin deposition. These pericapillary fibrin
deposits limit diffusion within tissues and the leaked leuko-
cytes stimulate the release of inflammatory mediators.2
Ultimately, the persistent inflammatory state induces tissue
necrosis and the venous leg ulcer forms. VLUs most
commonly occur at the malleolar level and can become
very large.3 Current standard treatment regimens are based
on the provision of extramural, mechanical compression
and limb elevation.4
There is no longer any debate as to the severity of the
socioeconomic impact caused by chronic venous insuffi-
ciency and VLUs. Today, the annual cost of treating VLUs
is over two billion US dollars, with actual, direct treatment
costs of approximately $10,000 per person per ulcer5 and
the average time to heal venous ulcers is 190 days.
These figures are exclusive of the economic losses
resulting from life style alterations, time lost from work
and frequent hospitalizations.
Development of an effective plan of care for patients
with venous leg ulcers must address multiple issues
including healing the active ulcer and recurrence preven-
tion. In order to achieve these obvious goals, adequate
treatment and management of comorbidities is essential.
Furthermore, ulcer-associated infection must be identified
and cleared before granulation and epithelial repair can
occur. Despite many advances in the development of
adjunctive wound care therapies, the average time to heal
venous ulcers remains at approximately 190 days.6
In 2006 we reported our experience with a cohort of 231
venous leg ulcer patients and our treatment measures that
resulted in an average time to heal of 29 days.7 In this
communication we report our retrospective experience with
897 additional patients and their 1249 venous leg ulcers.
The evolution of our treatment protocols has maintained
our average healing times but has significantly reduced
VLU treatment costs. This economic improvement is the
result of the addition of HCAa to our treatment regimens.
Costs and time to heal recurrent venous ulcers were no
greater than those associated with initial venous ulcers.
Those comorbidities which extended healing times
included active smoking, uncontrolled diabetes, use of
steroid medications, use of street drugs, the presence of
significant peripheral artery occlusive disease and very
large initial size.Patients and Methods
From June, 2006 to June 2014, 936 patients presented to
Lake Wound Clinics for treatment of 1311 venous lega Puracyn and Puracyn Plus Wound & Skin Care Solutions with Pre-
servatives Innovacyn, Inc. 3546 North Riverside Avenue, Rialto, CA
92377, USA. www.puracyn.com.ulcers. Of these, 39 patients with 62 venous ulcers were lost
to follow up before healing was complete. All venous leg
ulcer care protocols were based on standards of care and
were approved by institutional review boards and medical
directors. Details of this patient cohort, including comor-
bidities, are summarized in Table 1. Significant comorbid-
ities included diabetes mellitus, peripheral arterial
occlusive disease (PAD) with ABI , 0.80, smoking,
morbid obesity (BMI . 45) and the presence of one or
more multidrug resistant organisms, most notably methi-
cillin resistant Staphylococcus aureus (MRSA), vancomy-
cin resistant S. aureus (VRSA), Pseudomonas aeruginosa,
Escheriscia coli, Acinetobacter baumanii and Clostridium
difficile. All ulcers were cultured and, whenever appro-
priate, patients were referred back to their primary care
providers for systemic antibiotic treatment. Ulcer character-
istics, including volume, color and type of exudate, pres-
ence of odor, ulcer location, duration, surface area (cm2)
and maximum depth (cm) were recorded.
Initial treatment of all venous leg ulcers involved
cleaning and debriding foreign matter, debris and necrotic
material via application of copious HCA, under pressure if
necessary. Where needed, this was accompanied by abra-
sion using sterile gauze wet with HCA. In all cases
requiring sharp debridement, this was performed in an
appropriate surgical facility and within 10 days of
presentation.
Following initial treatment, all ulcers were dressed and/
or loosely packed with sterile gauze soaked with HCA. An
appropriately compressive, multilayered, overlying
bandage system, utilizing short-stretch or nonstretch mate-
rials, was constructed such that greatest compression was at
the ankle level. At no time did compression pressures
exceed arterial perfusion pressure in the extremity. Those
patients whose leg ulcers were complicated by the presence
of severe stasis dermatitis, 3241 pitting edema,
lipodermatosclerosis, lymphedema and/or serous fluid
transudation, underwent placement of a paste bandage
Unna’s Bootb applied over the ulcer dressing and extending
from the metatarsal heads to the knee. This bandage was
reinforced with sterile cotton gauze and overlying short-
stretch materials. In all cases requiring paste boot
bandaging, the dressing/bandage system was changed at
two and four days following initial application, then weekly
thereafter until the edema was resolved and healing was
determined to be advancing via monitoring of wound size
reduction. At every treatment occasion, digital photographs
of the wound were obtained and subjected to precise area
measurement through the application of planimetry
software.cb Unna’s Boot Dressing. Patient Technology Inc., Atlanta, GA 30360,
USA.
c Pictzar-CDM Photo Digital Planimetry Software. Bio-visual Tech-
nologies, LLC. 271 B Market Street, Elmwood Park, NJ 07407, USA.
Table 1 Patient characteristics (n 5 897 patients).
Age (years) 63 6 32a
Gender, n (%) Men 323 (36%) Women 574 (64%)
#VLUs on admission
n (%)
1
522 (58%)
2
289 (32%)
.2
86 (9%)
Comorbidities
Diabetes mellitus NIDDM 401 (44%) IDDM 263 (29%)
Active smoking 624 (69%)
Diabetes 1 smoking 222 (24%)
Morbid obesity
(BMI .45)
683 (76%)
Varicose veins 530 (59%)
Stasis dermatitis 671 (74%)
Lipodermatosclerosis 313 (34%)
CHF 196 (22%)
Recurrent VLU 216 (24%)
Duration of VLUs 36 6 22 months (range 1–120 months)
PAD (ABI , 0.80) 601 (67%)
n: # of patients; %: percent of cohort; VLUs: venous leg ulcers; PAD: peripheral arterial disease; ABI: ankle/brachial systolic pressure index; IDDM:
insulin-dependent diabetes mellitus; NIDDM: non-insulin dependent diabetes mellitus; BMI: body mass index; CHF: congestive heart failure.
aMean 6 1SD.
34 Journal of the American College of Clinical Wound Specialists, Vol 6, No 3The degree of bandage compression achieved was
controlled by continuous monitoring of digital artery
pressure pulse waveforms whenever possible.d In the
absence of detectable waveforms, a handheld 8 mHz
continuous wave Doppler instrument was used to insonate
digital or pedal arteries before, during and at completion
of bandaging. In all cases, developed bandage compression
pressures did not meet or exceed distal artery perfusion
pressure.
Except as described above, the frequency of dressing/
bandage system changes was dictated by the ulcer exudate
volume and bioburden mass. Heavily exudative wounds
initially required daily treatment with the hypochlorous
acid solution and concomitant compression bandage system
change. This schedule was quickly revised to provide fewer
clinic visits and wound treatments as healing progressed.
Once the VLUs were healed, and whenever possible,
patients were encouraged to wear appropriate compression
garments and to seek interventionalist consultation for
possible vein ablation to prevent ulcer recurrence.
Nutritional deficiencies common to venous ulcer pa-
tients have been described.7 Whenever appropriate, patients
were directed to increase their consumption of high quality
dietary protein and to use a vitamin/mineral supplement. In
diabetic patients, close monitoring and consistent control of
serum glucose levels to ,120 mg/dL is essential to the
healing process.
Venous leg ulcers that were infected with one or more
multidrug resistant organisms required extremely aggres-
sive treatment structured to reduce the bioburden mass andd Vicorder. Physicians Resource Network, Inc. 218 Shove Street, Fall
River, MA 02724. www.prnvascular.com.inhibit further growth.8 When use of systemic antibiotics
was contraindicated, we found that frequent, i.e., more
than three times per day, wound lavage with copious vol-
umes of HCA would achieve infection clearance with 2–5
days. It is important to note that, regardless of infection sta-
tus, all wound care was performed using contact isolation
protocols.
Microcirculatory integrity was assessed by measuring
tissue oxygen concentration (tcpO2)
e in the immediate,
periwound tissue.9,10 Measurements were obtained at the
time of initial presentation and 15–30 s following exposure
of wound tissues to HCA. Measurements were repeated at
72 h after initial exposure to HCA then as necessary.Results
It is well known that venous ulcer size alone is directly
proportional to healing times7 and, as seen in Table 2, this
was not different in our experience. However, the extent of
healing time increase appeared to be more directly related
to maximum wound depth rather than to surface area alone.
Very large VLUs, i.e., those with surface areas .40 cm2,
usually exhibited variable depths within the wound. These
could reach depths .10 cm in morbidly obese patients or
those with extreme edema. Wound tunneling and/or under-
mining did not affect healing times.
Healing times were extended in all VLU patients,
regardless of initial wound size, when more than one
significant comorbidity was present. These results aree Radiometer Copenhagen TCM 4 Series MKII. Radiometer Medical
ApS, DK-2700 Bronshoj. www.radiometer.com.
Table 2 Effect of initial VLU size on healing times.
# of patients
VLU dimensions
maximum area
(cm2)/depth (cm) # days to healed
26 ,5/,1 2–5
131 6/,1 2–7
122 7–20/1–3 9–27
454 21–30/2–4 9–31
101 21–40/5–10 14–40
63 .40/1–10 21–180
Bongiovanni Effects of Hypochlorous Acid on Venous Leg Ulcers 35illustrated in Table 3. Extended healing times occurred
when VLUs were complicated by the presence of diabetes,
smoking, use of steroid medications, use of street drugs,
peripheral artery disease and morbid obesity (BMI . 45).
Healing times were not extended, however, for recurrent
VLUs per se nor did the presence of congestive heart fail-
ure retard healing. Patients with varicose veins, stasis
dermatitis, lipodermatosclerosis, multidrug resistant infec-
tions and immunocompromise (HIV) did not experience
significant extensions of VLU healing times. Microcircula-
tory integrity, assessed via measurement of tcpO2 in
periwound tissues, was most compromised in diabetic
patients who were also smokers or who were positive for
significant PAD (Table 4). Following 15–30 s of exposure
to HCA, all patient categories exhibited increased tcpO2
except for those with significant PAD and/or smoking. At
72 h, those patients who exhibited increased tcpO2 in
response to initial wound bed exposure to HCA also
demonstrated persistent elevation of tcpO2 above baseline.
Diabetic patients and diabetics who smoke and/or who had
significant macrovascular PAD had trivial increases in peri-
wound tcpO2 that were not sustained for 72 h. Similarly,Table 3 Effect of comorbidities on healing times.
# of
patients Comorbidities present Days to heal
101 IDDM 17–34
393 NIDDM 6–41
42 IDDM 1 active smoking 36–117
34 IDDM 1 active
smoking 1
BMI . 35
44–186
26 NIDDM 1 PAD 1 active smoking 48–180
21 NIDDM 1 CHF 18–36
136 MDRI 1 NIDDM 16–39
211 IDDM 1 active smoking 1 MDRI 35–114
280 MDRI only 5–13
16 MDRI 1 age . 95 years 9–29
NIDDM: Noninsulin Dependent Diabetes Mellitus; IDDM: Insulin
Dependent Diabetes Mellitus; PAD: Peripheral Artery Disease (Ankle/
brachial systolic pressure index , 0.80); BMI: Body Mass Index; CHF:
Congestive Heart Failure; MDRI: Multi-drug Resistant Infection.nondiabetic patients who smoke also failed to exhibit resid-
ual increases in tcpO2 at 72 h.
Of concern in the treatment of VLUs is the development
of biofilm within the wound. Biofilm is a structural
community of microorganisms encased in a self-produced
extracellular matrix that is variably adherent to the wound
surface.8 The biofilm itself is avascular, resists the host im-
mune system and is not readily penetrated by antimicrobial
agents. Biofilms in wounds cause substantial healing
delays. In this study, biofilm presence within a wound
was determined via Flow-through Gram Stain.9 This
method reveals the presence of microcolonies within the
matrix structure and distinguishes a true biofilm formation
from visually similar appearances of exudate accumulation,
slough and mucoid debris.
Defeating biofilms and preventing their recurrence
required mechanical disruption of the biofilm with imme-
diate exposure to antimicrobial agents. We find that light
abrasion utilizing sterile cotton gauze soaked with HCA,
followed immediately by flushing the wound with more of
the solution, effectively destroys the extant biofilm in situ
and, with several repetitions over several days, prevents
biofilm from being reestablished. However, we have found
that the treatment episodes must be performed no more than
36 h apart to completely remove the biofilm. With incom-
plete removal, recurrent biofilm will retard all healing
stages.Discussion
All 1249 venous leg ulcers reported in this data set were
healed completely. The shortest healing times (2–5 days)
occurred in patients who were nonsmokers and who were
not diabetic. Patient age did not significantly affect healing
time. Extended healing times (.4 weeks) were found in
patients with larger initial ulcer size, greater ulcer depth
and with two or more comorbidities. Comorbidity combi-
nations of special note include diabetes accompanied by
significant peripheral artery disease (ABI , 0.8) and
diabetes accompanied by persistent smoking. The longest
healing times were encountered by patients for whom
compression therapy was contraindicated,10 e.g., diabetic
patients with severe arterial occlusive disease
(ABI , 0.6). Regardless, aggressive management with
HCA resulted in complete closure within 180 days in this
very difficult patient cohort.
Monitoring digital artery pressure pulse waveforms and/
or Doppler signals is a reliable method of controlling the
level of compression achieved during compression
bandaging. Additionally, effective compression bandaging
begins the wrapping at the level of the distal metatarsal
heads and terminates at the knee. Compression bandage
composition varied in response to wound and patient
conditions. Materials included paste wraps (Unna’s boot),
non-stretch or short-stretch materials. All compression
Table 4 Effect of comorbidities on microcirculatory response of periwound tissue to HCA exposure.
# patients Comorbidities
tcpO2 (mm Hg)
Initial 1HCA@30s mean 6 1 SD 1HCA@72 h mean 6 1 SD
101 IDDM 89 6 8 148 6 23 122 6 15
393 NIDDM 111 6 11 179 6 14 146 6 25
42 IDDM 1 active smoking 38 6 10 78 6 19 34 1 - 13
34 IDDM 1 active smoking 1 BMI . 35 33 6 11 75 6 20 29 6 9
26 NIDDM 1 PAD 1 active smoking 26 6 11 31 6 11 ,25
280 MDRI only 139 6 17 211 6 22 158 6 11
16 MDRI 1 age . 95 years 96 6 18 194 6 28 133 6 30
HCA: Superoxidized Solution stabilized with hypochlorous acid; tcpO2: tissue oxygen concentration; @30s: 30 s following exposure to HCA; @72 h:
72 h following exposure to HCA; Mean 6 1: Standard Deviation; IDDM: Insulin Dependent Diabetes Mellitus; NIDDM: Noninsulin Dependent Diabetes
Mellitus; BMI: Body Mass Index; PAD: Peripheral Artery Disease (Ankle/Brachial systolic pressure index , 0.80); MDRI: Multi-drug Resistant Infection.
36 Journal of the American College of Clinical Wound Specialists, Vol 6, No 3bandages were comprised of 2–4 layers and all materials
were a minimum of 4 inches wide to prevent development
of constricting bands.
All venous leg ulcers were cultured and antibiotic
sensitivities to all identified flora were obtained. When
appropriate, the patient was referred to his primary provider
for antibiotic therapy. We found that most patients with
large VLUs had undergone unsuccessful care attempts at
other facilities. Subsequently, infecting agents were often
iatrogenic and were multidrug resistant.11 When such infec-
tions occur in the diabetic VLU patient, rapid identification
of the responsible organisms is key to developing effective
strategies to eliminate the infection.
Perhaps the greatest advance in VLU care is the addition
of HCA to the treatment armamentarium. These aqueous
solutions of hypochlorous acid, even in trace amounts, will
kill most pathogens within 30 s of exposure. Additional
actions of HCA include reduction of mast cell degranula-
tion12 and active capillary dilation.13–15 The latter effect is
of great importance in the diabetic VLU patient since one
of the paradoxes in diabetes is the reduction of capillary
perfusion via arteriovenous shunting at the microcirculatory
level.13 The capillary dilation in turn elevates the tcpO2
within the wound. We have observed that this improvement
in periwound tissue oxygen concentration and perfusion
can be persistent to 72 h following exposure to the HCA.
Comorbidity combinations of diabetes, smoking and PAD
precluded significant increases in tcpO2 with no demon-
strable residual increase at 72 h following exposure to
HCA. In nonsmokers, accelerated angiogenesis, granula-
tion formation and epithelialization occur. Similar results
are obtained in nondiabetic VLU patients.
Additional factors in acceleration of healing of VLUs
includes management of diabetes mellitus to reach and
maintain target serum glucose levels of 80–120 mg/dL and
smoking cessation. Patients are strongly encouraged to
maintain normal physical activity and to ambulate freely
while undergoing VLU treatment. Frequent calf muscle and
venous foot pump action16 and the increased limb perfusionthat accompanies exercise can only improve the ulcer envi-
ronment and promote healing action and the increased limb
perfusion that accompanies exercise can only improve the
ulcer environment and promote healing.
It is well known that there are three factors that
contribute to failure of wounds to heal in a timely manner:
compromised perfusion resulting in diminished tissue
oxygen levels; invading flora and host immunological
impairment. We have found that the use of HCA in our
VLU care regimen successfully addresses the first two
factors and can favorably influence the third.
From this experience we conclude that aggressive
management of VLUs results in accelerated healing of
these wounds. The addition of HCA to our treatment
protocols has provided significant mircocirculatory amend-
ment of the damage caused by the presence of comorbid-
ities. Considerable bioburden reductions, via direct
antimicrobial effects, as well as prevention of biofilm
recurrence, quickly improve tissue conditions within the
wounds. Treatment cost reductions are facilitated by the
shortened healing times and the reduced need for expensive
wound care materials and modalities.
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